FDA Panel To Consider Calcitonin Drugs’ Need For Fracture Data In Light Of Potential Cancer Risk
This article was originally published in The Pink Sheet Daily
The Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committees will consider whether new calcitonin drugs for osteoporosis should show reduction in risk for fractures, a clinical benefit required of other osteoporosis medications.
You may also be interested in...
Saying its review found “no conclusive evidence of a causal relationship” between the products and cancer, agency is allowing continued marketing of Miacalcin and Fortical nasal sprays but limiting use to only those post-menopausal women for whom alternative treatments are not suitable.
Privately held firm believes oral calcitonin will enjoy several advantages over other osteoporosis therapies – ease of use compared to calcitonin nasal spray and safety compared to bisphosphonates.
Novartis announced Jan. 13 the elimination of nearly 2,000 positions in its U.S. General Medicines business in the wake of the termination of a key clinical study of Tekturna and in anticipation of the expiration of Diovan’s U.S. patent later this year.